The advanced therapies market in Italy

Advanced therapies are a category of innovative medical treatments that exploit advanced technologies to modify or manipulate genetic material, cells, or tissues with the goal of treating or curing complex and often incurable diseases.They represent an advanced frontier of personalized, targeted, and regenerative medicine, offering new treatment options for a wide range of genetic, oncological, degenerative, and autoimmune diseases. In recent years, innovative therapeutic technologies have been developed based on DNA, RNA, cells, and tissues, rather than chemically synthesized molecules. This broad set of therapeutic solutions is classified as Advanced Therapeutic Medicinal Products (ATMPs). ATMPs are true medicines derived from the remarkable advances made over the past 50 years in biotechnology and genetic engineering.

The value of the global market for advanced therapies shows significant growthfrom 2023 to 2030,with a compound annual growth rate (CAGR) of 16.80 percent.Starting from $31.6 billion in 2023, it is expected towill reach $93.7 billion in 2030. This represents an196% increaseover the forecast period.Conventional drug manufacturers, seeking to gain a competitive advantage, are looking at ATMPs as a lucrative source of revenue in future health care systems.

In Europe, 22 Advanced Therapies have been approved-6 of these have since been withdrawn from the market, ihe value of its market was $9.0 billion in 2023, and is expected to reach $27.2 billion in 2032, an increase by 202% in nine years at a CAGR of 13.0%.

As forour country, 8 Atmps are reimbursed and on the market, and another 6 are under evaluation. In the coming years, the market value is estimated to grow by 449% in a full scenario and 250% in a reduced scenario. One of the most interesting data is the national spending trend for ATMPs in Italy, which has grown by 6014% in four years, this reflects a significant increase in the adoption of innovative therapies, highlighting the growing importance of investing in advanced medical solutions to address complex diseases, while underscoring the need to balance access to these therapies with the economic sustainability of the health care system, as the rapid growth in investment presents major challenges in terms of cost management and equity in access to care.